Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences
September 21 2023 - 4:05PM
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage
biotechnology company with a mission to discover, develop and
deliver potentially curative therapies that address the underlying
causes of heart disease, announced today that poster presentations
related to its TN-201 and TN-301 programs will be presented at the
2023 Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific
Sessions taking place October 6, 2023, and at the Heart Failure
Society of America (HFSA) Annual Scientific Meeting occurring
October 6-9, 2023. Both meetings are being held this year in
Cleveland, Ohio.
TN-301 is Tenaya’s proprietary, highly selective small molecule
inhibitor of histone deacetylase 6 (HDAC6) being developed for the
potential treatment of heart failure with preserved ejection
fraction (HFpEF). Data to be presented at HFSA will include results
from the company’s Phase 1 clinical trial of TN-301 in healthy
adult participants. Tenaya has previously reported that TN-301 was
generally well tolerated and that target engagement was achieved.
The company will also present new data from preclinical studies
examining the effects of its HDAC6 inhibitor in combination with an
approved HFpEF treatment in a model of disease.
TN-201 is Tenaya’s lead gene therapy candidate being developed
for the treatment of hypertrophic cardiomyopathy (HCM) caused by
mutations in the Myosin Binding Protein C3 (MYBPC3). TN-201 is
designed to deliver a fully functional therapeutic MYBPC3 gene to
the heart muscle cells. At the HCMS meeting, Tenaya will highlight
the clinical trial design for its Phase 1b clinical trial in
nonobstructive patients with MYBPC3-associated HCM as well as
sharing interim data from an ongoing seroprevalence study.
Details of the presentations are as follows:
2023 HCMS Scientific SessionsFriday,
October 6, 20231:00 PM – 1:45 PM
EDTPoster Title: Low Seroprevalence of
Neutralizing Antibodies to Adeno-Associated Virus Serotype 9 (AAV9)
in Preparation for MyPeak-1, the First-in-Human Study of
TN-201, an Investigational AAV9-Mediated Gene Therapy for
Individuals with MYBPC3-Associated Hypertrophic Cardiomyopathy
(HCM) Presenter: Milind Desai, M.D., Director, HCM
Center and Director of Clinical Operations of Cardiovascular
Medicine, Cleveland Clinic
Poster Title: MyPeak-1: A Phase 1b Study to
Evaluate Safety and Efficacy of TN-201, an Adeno-Associated Virus
Serotype 9 (AAV9) Investigational Gene Therapy, in Adults with
MYBPC3-Associated Hypertrophic Cardiomyopathy (HCM)
Presenter: Laura Robertson, M.D., Vice President,
Clinical Development, Tenaya Therapeutics
To view full event programming, please visit the 2023 HCMS
Scientific Sessions website.
HFSA Annual Meeting 2023 Saturday,
October 7, 20238:00 AM – 8:30 AM EDT
e-Poster: Co-Administration of Inhibitors of HDAC6
and SGLT2 in Murine HFpEF Models Results in Additive Improvements
in Cardiac Structural and Functional Measures (#104)
Presenter: Farshad Farshidfar, M.D., Ph.D., Senior
Scientist, Cardiovascular Genetics, Tenaya Therapeutics
Location: Exhibit Hall ePoster Hub, Monitor 20
Sunday, October 8, 202312:45PM – 1:15
PM EDT ePoster: Phase 1 Clinical Trial Of TN-301, A Highly
Selective HDAC6 Inhibitor With Potential In HFpEF, Shows Target
Engagement (#417) Presenter: Gretchen Argast, Ph.D., Senior
Director, Translational Medicine, Tenaya Therapeutics Location:
General ePoster Viewing Session 7, Exhibit Hall ePoster Hub,
Monitor 23
To view full event programming, please visit the HFSA Annual
Scientific Meeting 2023 website.
About Tenaya Therapeutics Tenaya
Therapeutics is a clinical-stage biotechnology company committed to
a bold mission: to discover, develop and deliver potentially
curative therapies that address the underlying drivers of heart
disease. Leveraging its integrated and interrelated Gene Therapy,
Cellular Regeneration and Precision Medicine platforms and
proprietary core capabilities, the company is advancing a pipeline
of novel therapies with diverse treatment modalities for rare
genetic cardiovascular disorders and more prevalent heart
conditions. Tenaya’s most advanced candidates include TN-201, a
gene therapy for MYBPC3-associated hypertrophic cardiomyopathy
(HCM), TN-401, a gene therapy for PKP2-associated
arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301,
a small molecule HDAC6 inhibitor being initially developed for
heart failure with preserved ejection fraction (HFpEF). Tenaya also
has multiple early-stage programs progressing through preclinical
development. For more information,
visit www.tenayatherapeutics.com.
Contacts
InvestorsMichelle CorralVice President,
Investor Relations and Corporate CommunicationsTenaya
TherapeuticsIR@tenayathera.com
Julie SeidelStern Investor Relations,
Inc.Julie.seidel@SternIR.com
MediaWendy RyanTen Bridge
Communicationswendy@tenbridgecommunications.com
Tenaya Therapeutics (NASDAQ:TNYA)
Historical Stock Chart
From May 2024 to Jun 2024
Tenaya Therapeutics (NASDAQ:TNYA)
Historical Stock Chart
From Jun 2023 to Jun 2024